Latin America Diabetes Care Drugs Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 4.71 Billion |
| Market Size (2029) | USD 5.58 Billion |
| CAGR (2024 - 2029) | 3.48 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Latin America Diabetes Care Drugs Market Analysis
The Latin America Diabetes Care Drugs Market size is estimated at USD 4.71 billion in 2024, and is expected to reach USD 5.58 billion by 2029, growing at a CAGR of 3.48% during the forecast period (2024-2029).
The diabetic prevalence is high in countries in the Latin American region, and Mexico is known to have a high number of diabetic patients due to the growing prevalence of Type-2 diabetes in the country. The gradually growing obesity rate, combined with the genetic predisposition for Type-2 diabetes, is acted as a prominent driver for the increase in the Type-2 diabetic population over the last 40 years. Currently, close to 10% of the total population is living with diabetes. Diabetic patients in the Latin American region mainly suffer from Type-2 diabetes, and they accounted for close to 90% of the total diabetic population in 2021.
Based on drugs, the insulin segment holds a significant share in the market. Over 100 million people around the world need insulin, including all the people suffering from Type-1 diabetes and between 10% and 25% of people with Type-2 diabetes. Production of insulin is very complex, and there are very few companies in the market that manufacture insulin. Due to this, there is high competition between these manufacturers, who always strive to meet the patient's needs to supply the best-quality insulin.
Latin America Diabetes Care Drugs Market Trends
Oral Anti-Diabetic Drugs have the Highest Market Share in Current Year
The Oral Anti-Diabetes Drugs segment is expected to increase with a CAGR of over 3% during the forecast period, mainly due to the demand from the Type-2 diabetes population.
In Latin America, families pay about 40%-60% of diabetes costs out-of-pocket. Most private health insurance plans cover medical assistance, procedures, and hospitalization, not medication. Latin America is undergoing a remarkable epidemiological transformation. Diabetes and other chronic, nontransmissible diseases are now the leading health problems. Despite the large and growing number of diabetes cases, this geographic area invests limited financial resources in diabetes care. Metformin is the most commonly used oral diabetes medication. It's been around for a long time and has been extensively researched.
As a result, doctors frequently advise patients to start with metformin. If medication is required for gestational diabetes, metformin is the first choice of providers. According to the International Diabetes Federation, diabetes patients spent USD 966 billion in 2021, of which Type-1 diabetes patients spent a major chunk on insulin drugs. Few type-2 diabetes patients also depend on insulin. Although only 10% of the diabetes population is Type-1, their insulin intake is higher. Demand for oral drugs is driven by increased awareness about the benefits of diabetes cures for patients, especially in emerging economies. Primary care providers, nurse practitioners or PAs, endocrinologists, and internists frequently prescribe oral hypoglycemic agents.
However, educating the patient on lifestyle changes such as dietary changes and exercise therapy is critical. A dietary consultation is frequently required to educate the patient on a healthy diet. The patient should be encouraged to start an exercise program, quit smoking, and lose weight. Whatever oral hypoglycemic agent the clinician prescribes, interprofessional team members must be aware of the potential side effects and interactions with other medications, provide dietary and exercise advice, and collaborate to optimize therapeutic results.
Other factors, such as innovative drug development by major companies and the rise in the geriatric and obese population, may fuel the growth of the oral diabetes drugs market.
Brazil Diabetes Drugs Market is having Highest CAGR during the forecast period
In Brazil, the Brazilian health system is managed by each state and local health secretariat and is governed by the MOH. Furthermore, in many towns where the public sector cannot meet people's requirements, partnerships with private organizations have been put in place to increase access to PHC. The Brazilian health system provides coverage for medicines through programs that include 20% expanded access to essential medicines. Brazil offers an extensive free immunization program. Brazil faced numerous lawsuits over the last 20 years, demanding the coverage of high-cost drugs to treat diabetes and certain rare or low-prevalence diseases.
According to Universal Health Coverage 2022, the four nations, including Argentina, Brazil, Colombia, and Mexico, achieved an overall index of essential coverage of 76-77 percent, with households spending less than 25 percent of their income on health care and expanding access to primary healthcare systems and coverage for noncommunicable illnesses enhanced service coverage, while a rise in the number of qualified healthcare personnel enabled community outreach. Brazil's government is encouraging diabetes patients to use the medication to reduce the death rate in Brazil.
The programs like "Health Has No Price (SNTP)" conducted by the Brazilian Ministry of Health associated with private pharmacies in Brazil to provide diabetes patients with two types of insulin (regular human insulin and isophane insulin or NPH) and three oral antidiabetic medications (5 mg glibenclamide and 500 and 850 mg metformin) free of charge.
As a result, the diabetes care market in Brazil is predicted to expand gradually in the coming years.
Latin America Diabetes Care Drugs Industry Overview
The Latin American diabetes care drugs market includes several established global and local players. In Latin America, only a few players significantly share the need for branded drugs. However, the number of players for generic drugs is high, including several local ones. Novo Nordisk holds the largest share in the Latin American diabetes care drug market. Branded drugs from Eli Lilly and Boehringer Ingelheim Alliance are expected to record a high CAGR of more than 15% in the forecast period.
Latin America Diabetes Care Drugs Market Leaders
-
Novo Nordisk
-
Sanofi
-
Eli Lilly
-
AstraZeneca
-
Boehringer Ingelheim
*Disclaimer: Major Players sorted in no particular order
Latin America Diabetes Care Drugs Market News
- September 2023: Anvisa, Brazil's federal health regulator, approved tirzepatide. This injectable medication is designed to enhance blood sugar management in adults diagnosed with Type 2 diabetes. Manufactured by the renowned U.S. pharmaceutical company Eli Lilly, tirzepatide is marketed under the brand name Mounjaro.
- March 2022: Oramed announced ORMD-0801 (a new molecule) is being evaluated in two pivotal Phase 3 trials and can be the first oral insulin capsule with the most convenient and safest way to deliver insulin therapy. This drug is expected to be a game-changer in the insulin and oral anti-diabetes drugs markets. Oramed also develops an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).
Latin America Diabetes Care Drugs Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 Type
- 5.1.1 Insulin Drugs
- 5.1.1.1 Traditional Human Insulins
- 5.1.1.1.1 Humilin
- 5.1.1.1.2 Novolin
- 5.1.1.1.3 Insuman
- 5.1.1.2 Basal Insulin or Long-acting Insulin
- 5.1.1.2.1 Lantus
- 5.1.1.2.2 Levemir
- 5.1.1.2.3 Tresiba
- 5.1.1.2.4 Toujeo
- 5.1.1.2.5 Basaglar
- 5.1.1.3 Bolus Insulin or Fast-acting Insulin
- 5.1.1.3.1 Novolog/NovoRapid
- 5.1.1.3.2 Humalog
- 5.1.1.3.3 Apidra
- 5.1.1.3.4 FIASP
- 5.1.1.3.5 Admelog
- 5.1.1.4 Insulin Combinations
- 5.1.1.4.1 NovoMix
- 5.1.1.4.2 Ryzodeg
- 5.1.1.4.3 Xultophy
- 5.1.1.4.4 Soliqua/Suliqua
- 5.1.1.5 Biosimilar Insulin
- 5.1.1.5.1 Insulin Glargine
- 5.1.1.5.2 Other Biosimilar Insulins
- 5.1.2 Oral Anti-Diabetes Drugs
- 5.1.2.1 Biguanides (Metformin)
- 5.1.2.2 Alpha - Glucosidase Inhibitors
- 5.1.2.3 Dopamine D2 Receptor Agonist (Bromocriptin)
- 5.1.2.4 Sodium - Glucose Cotransport -2 (SGLT-2) Inhibitor
- 5.1.2.4.1 Invokana (Canagliflozin)
- 5.1.2.4.2 Jardiance (Empagliflozin)
- 5.1.2.4.3 Farxiga/Forxiga (Dapagliflozin)
- 5.1.2.4.4 Suglat (Ipragliflozin)
- 5.1.2.5 Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors
- 5.1.2.5.1 Sitagliptin (Januvia)
- 5.1.2.5.2 Saxagliptin (Onglyza)
- 5.1.2.5.3 Linagliptin (Tradjenta)
- 5.1.2.5.4 Alogliptin (Vipidia/Nesina)
- 5.1.2.5.5 Vildagliptin (Galvus)
- 5.1.2.6 Sulfonylureas
- 5.1.2.7 Meglitinide
- 5.1.2.8 Janumet (Sitagliptin and Metformin HCl)
- 5.1.3 Non-insulin Injectable Drugs
- 5.1.3.1 GLP-1 Receptor Agonists
- 5.1.3.1.1 Victoza (Liraglutide)
- 5.1.3.1.2 Byetta (Exenatide)
- 5.1.3.1.3 Bydureon (Exenatide)
- 5.1.3.1.4 Trulicity (Dulaglutide)
- 5.1.3.1.5 Lyxumia (Lixisenatide)
- 5.1.3.1.6 Janumet (Sitagliptin and Metformin HCl)
- 5.1.3.2 Amylin Analogue
- 5.1.3.2.1 Symlin (Pramlintide)
-
5.2 Geography
- 5.2.1 Brazil
- 5.2.2 Mexico
- 5.2.3 Rest of Latin America
6. MARKET INDICATORS
- 6.1 Type-1 Diabetes Population
- 6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
-
7.1 Company Profiles
- 7.1.1 Novo Nordisk
- 7.1.2 Sanofi
- 7.1.3 Eli Lilly
- 7.1.4 Takeda
- 7.1.5 Pfizer
- 7.1.6 Janssen Pharmaceuticals
- 7.1.7 Astellas
- 7.1.8 Boehringer Ingelheim
- 7.1.9 Merck and Co.
- 7.1.10 AstraZeneca
- 7.1.11 Bristol Myers Squibb
- 7.1.12 Novartis
- *List Not Exhaustive
-
7.2 Company Share Analysis
- 7.2.1 Novo Nordisk
- 7.2.2 Sanofi
- 7.2.3 Eli Lilly
- 7.2.4 AstraZeneca
- 7.2.5 Astellas
- 7.2.6 Janssen Pharmaceuticals
- 7.2.7 Merck and Co.
- 7.2.8 Other Companies
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityLatin America Diabetes Care Drugs Industry Segmentation
Controlling blood sugar through diet, oral medication, or insulin is the main treatment. Regular screening for complications is also required. Latin America, diabetes care drugs market, is segmented into product type (insulin drugs, oral anti-diabetes drugs, and non-insulin injectable drugs) and geography. The report offers the value (in USD) and volume (in units) for the above segments.
| Type | Insulin Drugs | Traditional Human Insulins | Humilin |
| Novolin | |||
| Insuman | |||
| Type | Insulin Drugs | Basal Insulin or Long-acting Insulin | Lantus |
| Levemir | |||
| Tresiba | |||
| Toujeo | |||
| Basaglar | |||
| Type | Insulin Drugs | Bolus Insulin or Fast-acting Insulin | Novolog/NovoRapid |
| Humalog | |||
| Apidra | |||
| FIASP | |||
| Admelog | |||
| Type | Insulin Drugs | Insulin Combinations | NovoMix |
| Ryzodeg | |||
| Xultophy | |||
| Soliqua/Suliqua | |||
| Type | Insulin Drugs | Biosimilar Insulin | Insulin Glargine |
| Other Biosimilar Insulins | |||
| Type | Oral Anti-Diabetes Drugs | Biguanides (Metformin) | |
| Alpha - Glucosidase Inhibitors | |||
| Dopamine D2 Receptor Agonist (Bromocriptin) | |||
| Sodium - Glucose Cotransport -2 (SGLT-2) Inhibitor | Invokana (Canagliflozin) | ||
| Jardiance (Empagliflozin) | |||
| Farxiga/Forxiga (Dapagliflozin) | |||
| Suglat (Ipragliflozin) | |||
| Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors | Sitagliptin (Januvia) | ||
| Saxagliptin (Onglyza) | |||
| Linagliptin (Tradjenta) | |||
| Alogliptin (Vipidia/Nesina) | |||
| Vildagliptin (Galvus) | |||
| Sulfonylureas | |||
| Meglitinide | |||
| Janumet (Sitagliptin and Metformin HCl) | |||
| Type | Non-insulin Injectable Drugs | GLP-1 Receptor Agonists | Victoza (Liraglutide) |
| Byetta (Exenatide) | |||
| Bydureon (Exenatide) | |||
| Trulicity (Dulaglutide) | |||
| Lyxumia (Lixisenatide) | |||
| Janumet (Sitagliptin and Metformin HCl) | |||
| Type | Non-insulin Injectable Drugs | Amylin Analogue | Symlin (Pramlintide) |
| Geography | Brazil | ||
| Mexico | |||
| Rest of Latin America |
Latin America Diabetes Care Drugs Market Research FAQs
How big is the Latin America Diabetes Care Drugs Market?
The Latin America Diabetes Care Drugs Market size is expected to reach USD 4.71 billion in 2024 and grow at a CAGR of 3.48% to reach USD 5.58 billion by 2029.
What is the current Latin America Diabetes Care Drugs Market size?
In 2024, the Latin America Diabetes Care Drugs Market size is expected to reach USD 4.71 billion.
Who are the key players in Latin America Diabetes Care Drugs Market?
Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca and Boehringer Ingelheim are the major companies operating in the Latin America Diabetes Care Drugs Market.
What years does this Latin America Diabetes Care Drugs Market cover, and what was the market size in 2023?
In 2023, the Latin America Diabetes Care Drugs Market size was estimated at USD 4.55 billion. The report covers the Latin America Diabetes Care Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Latin America Diabetes Care Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Latin America Diabetes Care Drugs Industry Report
Statistics for the 2024 Latin America Diabetes Care Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Latin America Diabetes Care Drugs analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
